2325 A study of the representativity of the NCIC, PRODIGE and MPACT phase III trials of gemcitabine-erlotinib, FOLFIRINOX and gemcitabine-nab-paclitaxel in patients with advanced pancreatic cancer treated in a real-life setting | Publicación